15 completed, 2 active not recruiting, 1 terminated, 1 withdrawn. 12 Phase 2, 5 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 636 | 2023-01-25 | 2026-09-10 |
| ABTECT - Maintenance ABX464, Placebo - Ulcerative Colitis | Phase 3 | Active not recruiting | Abivax S.A. | 1116 | 2023-01-16 | 2026-07-07 |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 639 | 2022-11-16 | 2026-09-10 |
| Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients ABX464, Placebo - Crohn Disease | Phase 2 / Phase 3 | Withdrawn | Abivax S.A. | 2022-09-19 | 2024-07-31 | |
| Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Active not recruiting | Abivax S.A. | 203 | 2021-12-03 | 2026-04-27 |
| Safety and Pharmacokinetics Study in Healthy Japanese Volunteers ABX464, Placebo - Healthy Volunteers | Phase 1 | Completed | Abivax S.A. | 48 | 2021-09-27 | 2023-01-26 |
| Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 Caffeine, ABX464, Fluvoxamine - Healthy | Phase 1 | Completed | Abivax S.A. | 59 | 2020-12-17 | 2026-11-09 |
| ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 ABX464, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Abivax S.A. | 509 | 2020-07-01 | 2025-11-26 |
| Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 217 | 2020-01-13 | 2026-05-06 |
| Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis ABX464 - Rheumatoid Arthritis | Phase 2 | Completed | Abivax S.A. | 40 | 2019-10-25 | 2025-11-17 |
| Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis ABX464 100 mg, ABX464 50 mg, ABX464 25 mg - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 355 | 2019-08-13 | 2025-11-28 |
| Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis ABX464 50mg, Matching Placebo, ABX464 100mg - Rheumatoid Arthritis | Phase 2 | Completed | Abivax S.A. | 60 | 2019-07-04 | 2023-02-15 |
| Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 22 | 2018-01-20 | 2025-05-29 |
| ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis ABX464, Placebo oral capsule - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 32 | 2017-11-16 | 2024-06-03 |
| A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults ABX464 150mg, ABX464 50mg - HIV Infections, Health Volunteers | Phase 1 / Phase 2 | Completed | Abivax S.A. | 36 | 2017-03-27 | 2023-03-31 |
| ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment ABX464, Placebo - HIV Infection | Phase 2 | Completed | Abivax S.A. | 30 | 2016-05-01 | 2024-09-19 |
| Safety, PK and PD Study of ABX464 in Untreated HIV Patients ABX464, Placebo - Human Immunodeficiency Virus Infections | Phase 2 | Completed | Abivax S.A. | 70 | 2015-01-01 | 2016-05-30 |
| Food Effect on Pharmacokinetic Parameters of ABX464 ABX464 Single dose, ABX464 Repeated dose - Healthy Volunteers | Phase 1 | Completed | Abivax S.A. | 48 | 2014-09-01 | 2016-04-08 |
| ABX464 First in Man Study ABX464 - Healthy Volunteers | Phase 1 | Completed | Abivax S.A. | 24 | 2014-03-01 | 2024-05-17 |
Colitis, Ulcerative (8) · Arthritis, Rheumatoid (2) · HIV Infections (2) · COVID-19 (1) · Crohn Disease (1)
Abivax S.A. (19)
Belgium (13) · France (12) · Spain (10) · Hungary (9) · Poland (9) · Czechia (8) · Germany (8) · Italy (7) · United Kingdom (7) · Austria (6) · Canada (6) · Serbia (5) · Slovakia (5) · Ukraine (5) · United States (4)
Bruce Sands, MD, PhD (3) · Severine Vermeire, MD, PhD (3) · Bram Verstockt, MD (1) · Laurence Desroys du Roure, PharmD (1) · Paul Gineste (1)
PMID 27799203, PMID 27999038, PMID 28507108, PMID 30800421, PMID 34436569, PMID 35641124, PMID 36075249, PMID 40417999